Singapore markets closed

VRTX Apr 2024 320.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
As of 12:50PM EDT. Market open.
Full screen
Previous close0.0500
Expiry date2024-04-19
Day's range0.0500 - 0.0500
Contract rangeN/A
Open interest88
  • Yahoo Finance Video

    Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal

    Vertex Pharmaceuticals (VRTX) is set to acquire Alpine Immune Sciences (APLN) for $4.9 billion in cash, gaining access to Alpine's treatments for kidney disease. The deal from Vertex values Alpine's stock at $65 a share, which is a nearly 67% premium from the stock's close on Tuesday. Yahoo Finance Anchors Josh Lipton and Julie Hyman discuss the trend of "pipeline in a product" deals. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino


    Vertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street Says.

    Vertex Pharmaceuticals is taking a big swing to secure its own second act: Late Wednesday, it announced a $4.9 billion deal to buy Alpine Immune Sciences which is developing a drug to treat a rare kidney disease. Vertex said it would pay $65 per share for Alpine, a 38.2% premium over the stock’s Wednesday closing price of $47.04. Shares of Alpine were trading at $64.19 early Thursday, while Vertex shares were up 1.2%.


    These Stocks Are Moving the Most Today

    Earnings at CarMax miss analysts’ estimates, Alpine Immune Sciences is being acquired by Vertex Pharmaceuticals for $4.9 billion in cash, Robinhood stock is downgraded, and Nike receives an upgrade.Read ...